|
|
 |
|
Viewing report
|
|
|
|
Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Datamonitor, Aug 2008, Pages: 53
Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Cubicin, Cubists major product, is approved for multiple indications in many countries. In the US, Cubicin is being marketed for the treatment of complicated skin structure infections (cSSI).
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights of this title
Cubist has one marketed product, Cubicin, an antibiotic from a class of antiinfectives called lipopeptides, for the treatment of complicated skin and skin structure infections, and for other blood-stream infections. The companys research and development programs include lipopeptide programs.
Cubist has research collaboration with Ilypsa to develop ILY103, a non-antibiotic, toxin binder therapy for the treatment of clostridium difficile associated diarrhea which is in preclinical trials.
Cubist derives its revenues from the product sales of Cubicin and other revenues which includes license agreements revenues, Small Business Innovation Research (SBIR) and grant revenue. Cubists total revenues increased at a CAGR of 103% during 2002-2006, from $11 million in 2002 to $195 million in 2006.
Key reasons to purchase this title
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Growth Strategies In Premium And Indulgent Food And Drinks To 2008: Increasing Profitability And Market Share
Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Global Market Review of Premium Beer ? Forecasts to 2013
The Growth of Premium Marketing
Developing Products With A Price Premium
Premium Company Profile: Depomed
Premium Company Profile Cytogen
Premium Company Profile Dyax
|
|
|
|
